Ablynx Partner Boehringer Ingelheim Corporation Initiates Phase 1 Study With Nanobody to Treat Alzheimer's Disease

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GHENT, Belgium, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels:ABLX] today announced that its partner Boehringer Ingelheim has dosed the first healthy volunteers in a Phase I clinical trial as part of the evaluation of a Nanobody® for the treatment of Alzheimer's disease. The start of the Phase I study triggers a milestone payment of €5 million to Ablynx.

Help employers find you! Check out all the jobs and post your resume.

Back to news